Capricor Therapeutics Inc... (CAPR)
Capricor Therapeutics Inc. (CAPR) Stock Price, Analysis & Data
| Bid | 5.9 |
| Market Cap | 411.62M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -129.42M |
| Beta | 0.53 |
| EPS (ttm) | -2.45 |
| PE Ratio (ttm) | n/a |
| Forward PE | -4.64 |
| P/B (ttm) | 1.46 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 10, 2026 |
| Ask | 7.4 |
| Volume | 8,403,525 |
| Avg. Volume (20D) | 4,594,972 |
| Open | 7.51 |
| Previous Close | 7.45 |
| Day's Range | 6.76 - 8.29 |
| 52-Week Range | 2.96 - 40.37 |
| Analyst | Hold |
| Price Target | 6 (-15.25%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About CAPR
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome prot...
Financial Performance
In 2025, Capricor Therapeutics's revenue was 0, a decrease of -100% compared to the previous year's 22.27M. Earnings were -105.04M, an increase of 159.58%.
Financial StatementsAnalyst Forecast
According to 4 analyst ratings, the average rating for CAPR stock is "Hold". The 12-month stock price forecast is 6, which is downside of 15.25% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
